InVivo Therapeutics Announces New Stock Symbol ‘NVIV’

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, announced today that the trading symbol for its stock, trading on the OTC Bulletin Board, has been changed from NVIV.OB to NVIV.

The OTC Markets, which is the electronic quotation system for all OTC securities, has dropped .OB and .PK from the stock quote information it provides to online financial portals. Investors seeking stock quote information from online financial portals should now use simply NVIV to obtain a quote.

We have received numerous questions regarding our stock price being stuck at $2.20 per share for the last few weeks as that was the last price of the stock under the old trading symbol, said InVivo Therapeutics CEO Frank Reynolds. Please refresh your symbols in your watch lists or portfolios to obtain an accurate price.

This change in the trading symbol has no negative impact on InVivos continued successful performance.

Corporate achievements include:

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visitwww.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Companys ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Companys products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

More here:
InVivo Therapeutics Announces New Stock Symbol ‘NVIV’